RESP-X   Click here for help

GtoPdb Ligand ID: 14217

Synonyms: COT-143 | INFEX702
Compound class: Antibody
Comment: RESP-X is a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa. It is being developed as an anti-virulence therapy for P. aeruginosa infections in patients with non-cystic fibrosis bronchiectasis.
References
1. Leonard C, Savage V, Ooi N, Dobmeyer J, Lindsay D, Walker W, Fitzgerald R. (2024)
Late Breaking Abstract - Exciting phase 1 data on RESP-X, a novel monoclonal antibody targeting a key virulence mechanism of Pseudomonas aeruginosa, with potential as a treatment to reduce exacerbations in non-CF bronchiectasis.
Eur. Respir. J., 64 (68). DOI: 10.1183/13993003.congress-2024.OA2783
2. Leonard CT, Dobmeyer J, Ooi N, Savage V, Nield K, Lindsay D, Schmidt S, White R, Fitzgerald R, Walker L. (2026)
Positive Phase 2a Study Results on Resp-x (infex702), a Highly Potent Anti-virulence Monoclonal Antibody in Development to Reduce Exacerbation Frequency in Pseudomonas Aeruginosa-colonised Non-cystic Fibrosis Bronchiectasis (ncfb) Patients.
Am. J. Respir. Crit. Care Med., 212 (Supplement 2). DOI: 10.1093/ajrccm/aamag286.106
3. Numata S, Hara T, Izawa M, Okuno Y, Sato Y, Yamane S, Maki H, Sato T, Yamano Y. (2024)
Novel humanized anti-PcrV monoclonal antibody COT-143 protects mice from lethal Pseudomonas aeruginosa infection via inhibition of toxin translocation by the type III secretion system.
Antimicrob Agents Chemother, 68 (10): e0069424. [PMID:39269189]